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Despite numerous clinical trials demonstrating that microwave hyperthermia
is a powerful adjuvant modality in the treatment of cancers, there have been
few instances where this method has been applied to brain tumors. The
reason is a combination of anatomical and physiological factors in this site
that require an extra degree of accuracy and control in the thermal dose
delivery which current systems are not able to provide. All clinical applicators
available today are in fact based on a single-frequency technology. In terms
of treatment planning options, the use of a single frequency is limiting as
the size of the focal spot cannot be modified to accommodate the specific
tumor volume and location. The introduction of UWB systems opens up an
opportunity to overcome these limitations, as they convey the possibility to
adapt the focal spot and to use multiple operating frequencies to reduce the
power deposition in healthy tissues.
In this thesis, we explore whether the current treatment planning meth-
ods can be meaningfully translated to the UWB setting and propose new
solutions for UWB microwave hyperthermia. We analyze the most commonly
used cost-functions for treatment planning optimization and discuss their suit-
ability for use with UWB systems. Then, we propose a novel cost-function
specifically tailored for UWB optimization (HCQ). To solve for the HCQ, we
further describe a novel, time-reversal based, iterative scheme for the rapid
and efficient optimization of UWB treatment plans. We show that the com-
bined use of these techniques results in treatment plans that better exploit the
benefits of UWB systems, yielding increased tumor coverage and lower peak
temperatures outside the target. Next, we investigate the design possibili-
ties of UWB applicators and introduce a fast E-field approximation scheme.
The method can be used for the global optimization of the array parame-
ters with respect to the multiple objectives and requirements of hyperthermia
treatments. Together, the proposed solutions represent a step forward in the
implementation of patient-specific hyperthermia treatments, increasing their
accuracy and precision. The results suggest that UWB microwave hyperther-
mia for brain cancer treatment is feasible, and motivate the efforts for further
development of UWB applicators and systems.
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Cancer represents the second leading cause of death worldwide [1]. While
the survival rates for most types of cancer have seen a steady improvement
over the past decades, certain tumor types seem to have been excluded from
this positive trend. For instance, cancers of the central nervous system, the
pancreas, the bowel and the lungs [2]. The brain in particular remains one of
the most challenging sites to treat, as expressed by an extremely low 5-years
survival rate of 22% in the 20-44 age group [3]. Together with short life ex-
pectancy, currently available brain cancer therapies are also associated with
potentially severe long-lasting side effects. Survivors often experience seizures,
walking difficulties, speech problems, and a wide range of others disorders for
the rest of their lives [4]. The situation is worse in pediatric patients, where
brain tumours are the second most common form of cancer after leukaemia.
Modern therapies can cure more than 75% of all children struck with cancer
[5], but they entail severe acute and long-lasting side effects. Even low doses
of ionizing radiation to the brain can cause cognitive impairment as well as
growth disorders [6]–[8]. Therefore, there is a strong need for complimentary
therapies with low toxicity that can reduce the amount of radiation adminis-
tered to the patient without compromising the treatment outcome.
3
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Rate of Change (5-years rolling average)
Bladder cancer
Brain and nervous system cancer
Breast cancer
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Colon and rectum cancer
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Tracheal, bronchus, and lung cancer
Uterine cancer
Figure 1.1: Overall age-standardized rate of change of the cancer-related incidence,
mortality and amount of years lived with disability considering patients
all over the world over the past 30 years. The trend for brain and
nervous system cancers is highlighted in solid red. While the absolute
incidence of these cancers is lower compared to other types, the relative
figures indicate that this measure is increasing for brain cancers. In
particular, the quality of life of brain cancer survivors, unlike most
other patients, has never really improved over the last decades, as
shown by the bottom left figure.
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1.1 Thesis concept
Hyperthermia appears to be an ideal candidate for this purpose. After
a number of results below expectation in the 1980s followed by a period of
skepticism [9], caused mostly by technological limitations and lack of knowl-
edge over the complex, temperature-dependent biological mechanisms in the
human body, this form of thermal therapy has seen a major revival in the
past decade [10]. Recent meta-analyses and reviews have managed to collect
an impressive amount of literature documenting its positive adjuvant effects
when applied in combination with radio- or chemo-therapy [11]–[14]. These
analyses have demonstrated a significant increase in tumor control probability
and even survival rate in some cases with no added toxicity [15], [16]. Yet,
to date only few clinical trials have seen the application of microwave hyper-
thermia as a treatment modality for brain tumours, albeit with encouraging
results [17]–[19]. The reason behind this lack of confidence is the imperfect
technology used to accurately deliver the prescribed thermal dose in the prox-
imity of critical organs. For instance, in the glioblastoma study [19], despite
the improved clinical outcome, homogeneous therapeutic temperatures were
difficult to achieve with the interstitial methods used. Thanks to the expo-
nential growth of computational capabilities and development of microwave
technology for communication purposes, today we are able to simulate with
far greater accuracy the scattering of high-frequency electromagnetic waves
inside the body and provide better control of the radiation during treatment.
This enables the design of external antenna arrays capable of focusing the
heat selectively into the tumour, thus achieving thermal therapy in its most
sophisticated form: deep microwave hyperthermia for brain cancer treatment.
1.1 Thesis concept
Intracranial heating is a demanding task. In order to achieve high thermal
doses and complete tumor coverage in such a delicate area, microwave hyper-
thermia systems have to be refined in all their parts to reach the necessary
accuracy and precision. Today’s loco-regional systems, which are successfully
employed in the treatment of abdomen, extremities and neck cancers, rely on
a single and fixed operating frequency. This choice comes with many bene-
fits, such as the possibility of being implemented via a simple and robust RF
design, but it also involves some limitations. The main constraint of single-
frequency systems is the inability to adapt the size of the focal spot to the
5
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Figure 1.2: Cancer-related incidence, mortality and amount of years lived with dis-
ability considering young patients all over the world over the past 30
years. The trend for brain and nervous system cancers is highlighted in
solid red. Brain tumours are the most common solid-type cancers in
children, but unlike leukemia, their incidence has not been decreasing
over the past decades. A slight improvement in mortality rates has
however led to a huge increase in the amount of years spent with dis-
abilities for these patients, indicating a strong need for therapies with
lower toxicities and less after-treatment complications.
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particular tumor size and location. We strongly believe that UWB systems
are necessary to fulfill the rigorous requirements of microwave hyperthermia
treatments in the brain, since they introduce a new degree of freedom in the
formation of the power deposition pattern inside the body. The shift towards
USB systems is however not trivial, and it implies a revision of hyperthermia
treatment planning algorithms, together with a careful redesign the RF steer-
ing systems. A second limitation comes from the antenna array applicators,
which nowadays are meant to target a body region rather than a particular
tumor. In our opinion, a generic applicator will always struggle to reach op-
timal heating patterns in brain cancer patients, due to the added difficulties
in the treatment of this site. A paradigm shift in the applicator design is
thus necessary: from regional applicator arrays to target-specific ones. Ex-
ploring possible array designs and validating them for each case, however,
is a challenging task. Fast array simulation techniques and treatment plan-
ning methods are necessary to let us survey all the possible combinations of
antennas and frequencies for a specific patient. In this thesis we focus on
the development of fast UWB treatment planning algorithms and on the de-
sign of (patient) specific (brain) applicators, which will help addressing these
questions.
1.2 Thesis outline
This thesis is organized as follows. In Chapter 2, the concept of hyperther-
mia therapy is introduced along with a brief summary of the main challenges
faced and current clinical implementations. Then the scope is narrowed down
to the application of microwave hyperthermia (MW-HT) for deep-seated tu-
mours. The implications of moving towards a UWB setting on the applicator
design and treatment planning optimization are subsequently explained, and
the potential benefits of UWB treatments for brain cancer are discussed.
Chapter 3 begins with an overview of the challenges faced in electromagnetic
and thermal modelling. The treatment planning (TP) phase of MW-HT,
which is extensively based on computer simulations, is described and several
approaches to this problem are discussed. The author’s novel contribution
of a iterative time-reversal method for TP is reported and compared to the
clinical standard and to other solutions reported in the literature.
The investigations carried out on how to put together an optimal antenna
7
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array applicator for MW-HT are reported in Chapter 4. Here, the design
of the array is discussed under the UWB perspective. A field interpolation
technique to quickly evaluate many potential array configurations is described
and utilized to propose a number of nearly-optimal applicator designs for a
specific patient and tumour anatomy. The method is further applied to the
specific case of a medulloblastoma patient and a promising helmet applicator
design is obtained by means of global optimization.
Chapter 5 includes a discussion on the hardware needed to implement such
a helmet applicator and describes the challenges and ongoing efforts of manu-
facturing a robust MW-HT system for head, neck and brain cancer treatment.
The chapter ends with conclusive remarks and a layout of future work. The
author’s paper contributions are summarized thereafter and are reported at




Thermal therapy has been known to human kind as a way to treat diseases
ever since the ancient times. In many examples throughout history, physicians
attempted, often successfully, to cure diseases by means of induced fever or
burn malignancies with incandescent sticks or blades [20]. Heat is also a
fundamental component of the body’s natural self-defense mechanisms. Local
and systemic responses, triggered by the presence of pathogens, are often
associated with inflammation or fever, implying a temperature increase in the
tissue or body, respectively. In the past, the temperature rise was seen as a
mere consequence of the increased metabolic activity necessary for the fight,
but nowadays this is no longer the general view among immunologists. In
fact, it has become more and more evident that the elevated temperature has
a role in itself, enhancing the activity and efficacy of our immune system, even
in the absence of pathogens [21].
With time, researchers have unveiled a number of microscopic and macro-
scopic, local and systemic, biological and physiological effects of heat and
elevated temperature on the body [22], [23]. These mechanisms point towards
a strong therapeutic potential of artificial temperature elevation in the treat-
ment of cancers and other diseases. Treatment methods relying on the external
9
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administration of heat are nowadays divided into two categories: thermal ab-
lation and hyperthermia. The aim of the first is to kill the tumor cells by
literally burning them, which requires temperatures > 45 ◦C. The method is
highly localized and carried out by means of invasive procedures [24]. Modern
mild hyperthermia for cancer treatment, on the other hand, is defined as the
elevation of the tumor temperature to 40 ∼ 44 ◦C [25]. This range of tem-
peratures has been shown to trigger a number of mechanisms at a molecular
and tissular level that considerably improve the tumor response to traditional
cancer therapies such as radio- and chemo-therapy [26], [27], Fig. 2.1. Hyper-
thermia is thus seen today as a potent adjuvant modality to these two main
practices, and its inclusion has been shown to enhance survival rate and tumor
control probability for a number of cancer types [10]–[13], [16].
Figure 2.1: Summary of the additive and synergistic effects of mild hyperthermia
on radiotherapy and chemotherapy, from [28]. Vasodilation increases
blood perfusion resulting in deeper penetration of chemotherapeutic
agents; increased oxygenation enhances the induction of DNA breaks
by radio-therapy; disturbances in the tumour micro-environment stim-
ulate the immune responses; inhibition of the DNA repair mechanisms
enhances the damage provoked by radio- and chemo-therapy.
Unfortunately, the optimal temperature of 43 ◦C, as suggested by biological
studies [28], [29], is usually not achieved inside the target in clinical practice
[30]. The reason behind this is the imperfect technology utilized in delivering
10
the prescribed thermal dose to the target volume [31]. From a biomedical
engineering perspective, the task of reaching a predefined and controlled tem-
perature distribution in a biological tissue in-vivo is indeed a challenging task.
The ability of living organisms to maintain their homeostasis is extraordinary
and the body will use all means to counteract the artificially administered
heat. As soon as the local temperature deviates from the set level of 37 ◦C,
blood perfusion and sweating increase to remove the excess heat. This re-
sponse is non-linear and can vary significantly from patient to patient. This
renders external heat delivery a demanding technique whose implementation
requires careful and robust design. On top of this, the monitoring of the ac-
tual temperature distribution inside the patient during treatment, necessary
for the assessment of the thermal dose, is by no means a trivial task [32]. All
these aspects have to be taken into account and addressed for when designing
a reliable system for hyperthermia treatments.
Figure 2.2: Graphic summary of the techniques available for the administration of
the thermal dose in hyperthermia treatments, from [33].
11
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The list of technologies available today to deliver hyperthermia is long [33],
Fig. 2.2. However, only few of them have been applied in the treatment of
brain tumors. Among the techniques proposed in the past two decades to
selectively induce a temperature increase [34], only interstitial hyperthermia,
magnetic nano-particle hyperthermia and high-intensity focused ultrasound
(HIFU) have been clinically applied to deep seated brain tumors. Interstitial
hyperthermia combined with brachytherapy applied to high-grade glioblas-
tomas has been demonstrated to be a safe and attractive modality to improve
the survival of these patients [35], [36]. Despite the promising results in terms
of an improved treatment outcome, homogeneous tumor temperatures were
difficult to achieve with the interstitial applicators used. More recently, the
use of magnetic fluid hyperthermia to enhance heating precision was inves-
tigated [37]. Results demonstrated an increase in tumor temperatures and
higher overall survival than conventional therapies [38], [39]. The disadvan-
tage of this technology lies, however, in the direct injection of iron oxide
nanoparticles into the tumor. These nanoparticles can remain in the treated
area for a lifetime, thus hindering the patient from undergoing future MRI
scans, which is, despite the (minimally) invasive procedure, a clear limitation
of this technique. HIFU provides localized energy delivery through small vol-
umetric sonifications from an ultrasound phased array transmitter to destroy
intracranial lesions by thermocoagulation [40]. Heating of large volumes, as
is usually the case for childhood brain tumors, is nevertheless still demanding
with the present technology. Furthermore, ultrasound based treatments suf-
fer from high energy losses in the bone structures, and despite novel technical
solutions, its implementation in the brain will very likely be limited to tumors
located centrally and at a distance from the skull [41].
Microwave hyperthermia, which relies on the non-invasive deposition of fo-
cused EM energy into the tumor by a phased array of antennas [14], [25], has
the potential to circumvent these limitations and achieve therapeutic tem-
peratures in brain tumors without the need for surgical interventions [42].
However, several technological challenges must first be resolved to provide the
centimeter-scale spatial control needed to compensate for vascular cooling in
living tissues and to deal with the small anatomical features of the head. The
typical setup for a non-invasive microwave hyperthermia treatment is shown
in Fig. 2.3. The patient lies on a treatment bed or chair and a so-called ap-
plicator is placed around the region to be treated. The applicator consists of
12
Figure 2.3: Microwave hyperthermia for cancer treatment, conceptual drawing.
a phased array of antennas and a water bolus. The water bolus has two pur-
poses: to realize an impedance match between the antenna and the patient,
and to cool the skin and dampen superficial hot-spots. Each channel of the
applicator array is independently steered in amplitude and phase, to shape
the interference patter and power loss deposition inside the patient. In the
case of a discrete multi-frequency UWB system, each frequency can be steered
independently from the others, and the power loss is given by the superposi-
tion of the interference patterns at all frequencies. The RF amplifying system
must deliver the phase-locked signals with adequate accuracy and precision.
Deviations of amplitude and phase in modern hyperthermia systems do not
exceed ±5% and ±5◦ respectively from the nominal value [43], [44]. Because of
the high power that each channel is supposed to deliver for adequate heating,
the antennas must exhibit high directivity and low cross-coupling. Current
clinical hyperthermia systems operate over a narrow frequency band, which
makes their construction relatively simple. Examples are 70, 100 MHz for the
pelvic and abdominal region [45], [46] and 434 MHz for the head and neck
[47]. Of course, if an UWB hyperthermia system is to be deployed, both the
antennas and the RF cascade must be adapted to operate across the entire
target frequency band. This represents an additional layer of difficulty with
respect to the current technology.
Despite the impressive advances that the field of microwave hyperthermia
13
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has witnessed in the past 30 years, present treatments (still) suffer from the
inability to adequately heat tumors in several regions that could benefit from
this type of therapy. This has resulted, among other things, in the study of
Sneed et al. [36] being the sole experience with microwave heat delivery into
the brain, albeit with promising results. We believe that the lack of accurate
thermal dose delivery and reliable temperature monitoring in this region has
made it extremely difficult to properly trace a dose-effect relationship. Fortu-
nately, there is mounting evidence that the development of UWB applicators
capable of operating at different frequencies can lead to improved target cov-
erage and hot-spot suppression [48]–[50], which might once more motivate
efforts for the development of brain applicators [51]–[53].
An UWB system can exploit the complementary interference patterns gen-
erated by different frequencies to increase the net average power delivered to
the tumor while reducing the absorption in healthy tissues. This is expected
to benefit treatments in the brain region, which is characterized by a combi-
nation of anatomical and physiological factors that require an extra degree of
accuracy in the formation of the heating pattern. The cerebral tissue is more
sensitive to deviations in temperature than other tissues [54], and the pres-
ence of cerebrospinal fluid can cause strong and treatment-limiting hot-spots
to appear in the immediate vicinity of the brain. Yet, recent developments
suggest that an implementation of microwave hyperthermia for brain cancer
treatment is within reach [42]. To conquer the trust of the oncologists and
the medical community, however, real clinical evidence is necessary. A crucial
precondition to successful clinical trials, in turn, is the development of reliable
hyperthermia systems and robust treatment planning methods. In the follow-
ing chapters, we discuss how treatment planning optimization algorithms can
be extended into the UWB domain, and how these can be used in the design




Treatment planning is a fundamental stage of microwave hyperthermia treat-
ments [55]. It consists in several steps aiming at determining the set of steering
parameters that yield high temperatures in the tumor while sparing the sur-
rounding healthy tissues from excessive heat, Fig. 3.1. In the case of deep
hyperthermia administered by phased array applicators, the steering param-
eters are the amplitude and phase of each antenna. Varying these settings
affects the wave propagation inside the patient and shapes the EM interfer-
ence pattern and consequent power deposition. Historically, the tuning of the
steering parameters in single-frequency applicators with up to a handful of
independent steering channels has been performed manually with the help of
EM probes [56]. The task is often carried out qualitatively, and with little in-
formation about the actual resulting distribution of the power losses inside the
patient. The clinical experiences gathered over time, however, revealed that
it is crucial to identify the location and severity of power deposition peaks, as
these often lead to hot-spots in healthy tissues thereby effectively limiting the
maximum achievable temperature in the target [57]. Today, clinical applica-
tors can reach up to 12 independently steered channels [47], and the problem
of determining the optimal amplitude and phase settings for each antenna has
15
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become non-trivial. The situation is further complicated if an UWB system
is to be deployed: the task of choosing the optimal combination of operating
frequencies and their weight in the treatment plan is quite involved and a
global optimum is hard to determine [58].
Figure 3.1: Stages of microwave hyperthermia treatment planning, from [59].
Hot-spots can arise in the healthy tissues as these lie in the path between
the antennas and the target. As a consequence of their relatively high con-
ductivity at microwave frequencies [60], tissues tend to absorb energy from
the traveling wave and heat up. This is aggravated by the anatomical het-
erogeneity and the presence of sharp interfaces between tissues with different
dielectric properties, which cause multiple reflections and localized intensity
peaks. The imperfect interference pattern generated by the limited-aperture
phased array also contributes to the uneven localization of the energy losses.
The threshold temperature for hot-spot related pain complaints is typically
≈ 45 ◦C [61]. However, in the brain, damage and thermal related toxicity
can be detected already with temperatures above ≈ 42 ◦C [54]. To manage
occurring hot-spots before and during treatment is therefore mandatory. Su-
perficial hot-spots within depths of one to two centimeters from the skin can
be suppressed by applying a water bolus circulated with cool water. Hot-spots
that arise in deeper locations, however, are more difficult to manage. The sole
strategy to suppress or limit those hot-spots is to reduce the power deposition
at those locations while preserving the constructive interference (focus) in the
target volume. The problem is challenging, but it can be tackled with the
help of optimization algorithms.
Tons of methods to determine the optimal amplitudes and phases for an ap-
plicator array that yield satisfying target coverage and limited hot-spot tem-
peratures have been reported in the literature and are still subject of ongoing
research [59], [62]. These methods can be classified into two main categories:
specific absorption rate (SAR) based and temperature (T) based. SAR based
16
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techniques rely on the assumption that the SAR distribution is predictive of
the temperature distribution in the patient [63]. However, since the thermal
response of the body can be highly non-linear, SAR-based optimizers can yield
sub-optimal, while still clinically relevant, steering parameters. T-based opti-
mizers, on the other hand, have evolved to include complex non-linear aspects
such as discrete vasculature and systemic response under thermal stress [64].
Ideally, a full implementation of T-based treatment planning in the clinical
routine is desirable, since temperature is the objective dose. In current prac-
tice, however, the theoretical benefits of T-based optimizations are somewhat
diminished due to the lack of accurate estimations of the thermal tissue prop-
erties [65]–[67]. These thermal properties, and blood perfusion in particular,
exhibit large variations across patients and even at individual level in differ-
ent treatment sessions. In summary, both SAR-based and T-based approaches
are being clinically applied as both require adjustments during treatment in
response to hot-spots [57], [68]. Considering the current equivalence of these
two approaches, in this thesis we consider only SAR-based treatment planning.
The choice is motivated by the fact that SAR-based optimization requires less
computational resources, thereby allowing for quicker comparisons among a
large number of possible treatment plan solutions.
3.1 Patient modeling
In today’s state-of-the-art treatment planning for microwave hyperthermia,
virtual patient models are used to simulate the wave propagation in the body
in conjunction with the specific applicator model in use [62]. The patient
models are obtained from CT or MRI scans and subsequently segmented into
a discrete number of tissues [69]. How detailed the segmentation should be,
depends on the frequency utilized by the applicator as well as on the region
to be treated. A study to determine the impact of the number of segmented
tissues in the pelvic region on the SAR distribution revealed the importance
of properly representing high water content tissues [70]. On the one hand, the
set of segmented tissues must be limited to spare computational resources and
avoid over-fitting. On the other hand, all the spatial variations in electromag-
netic properties that might affect the wave propagation have to be captured,
as well as all critical healthy tissues where a strict temperature limit must be
enforced.
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(a) Sagittal (b) Transverse
Figure 3.2: Example of a patient model, discretized at a resolution of 2 mm. The
model encompasses the upper head and is terminated at the level of
the nose to reduce its computational weight. The applicator and water
bolus are also included (blue shape). The target, a 30 ml meningioma,
is outlined in white.
A second aspect of patient modeling is the resolution. In the pelvic area,
for instance, clinical treatment planning tools utilize resolutions of 2.5×2.5×
2.5 mm for both simulation and optimization purposes [57]. Conversely, in the
neck region, the current practice is to perform a high-resolution simulation of
the wave propagation followed by a lower resolution treatment planning opti-
mization step at 5×5×5 mm [68], [71]. This is done to keep the computational
burden of the optimization process at bay and enable online and real-time re-
adaptation of the steering parameters upon patient complaints. Whether this
resolution is sufficient to capture the wave scattering in small anatomical fea-
tures such as nerves and bones is however uncertain. In intracranial heating,
the presence of the skull, whose thickness can be as little as 3 mm [72], is
particularly relevant, as bone exhibits notably different dielectric properties
than soft tissues. Furthermore, the space discretization carried out for the
sake of computer analyses and simulations is usually realized on hexahedral
grids. This implies that the maximum allowable voxel size has to be further
restricted in order to properly sample the skull’s curvature. Another criti-
cal issue is the presence of cerebrospinal fluid, since its high conductivity at
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microwave frequencies makes this tissue prone to overheating. The intercon-
nected cavities where this fluid is free to move are also characterized by narrow
passages and thin strati. Accordingly, all computations in this work have been
realized on patient models with resolution 2× 2× 2 mm.
The subsequent phase in patient modeling is the assignment of the dielectric
and thermal properties to the segmented tissues. As already mentioned, tis-
sue properties exhibit large variations across the population and are in general
difficult to obtain for the specific patient. Such variations depend on the per-
son’s age [73], fitness level, and other factors. The variation is typically larger
for thermal properties than for electromagnetic ones [67]. In addition to the
variance across the population, intra-patient variations can also be possible
between subsequent treatment sessions. This is due to the body adapting to
environmental and behavioral changes to better preserve its homeostasis. Fac-
tors that can affect the tissue response include the ambient temperature, the
patient’s hydration level [74], or whether the patient has carried out any recent
physical activity. Finally, most thermal tissue properties, and blood perfusion
in particular, are dependent on the local temperature itself [75], [76]. This
temperature dependence can strongly affect the hyperthermia treatment plan
and ultimately the effectiveness of the treatment. Nevertheless, a useful and
relevant estimation of the wave propagation and resulting thermal distribution
inside the treated area can still be obtained with a good degree of approxima-
tion by relying on tissue property databases with modified perfusion values
[65], [77]. The uncertainty in the resulting SAR and temperature distribu-
tions due to tissue property variations has been estimated to be around 20 %
[78]. In the works reported here, all the healthy tissue properties have been
obtained from the IT’IS database [60], which represents a valuable collection
of literature values from decades of measurements. To mimic the presence
of a tumor, the delineated target volumes have been filled with a material
exhibiting properties equal to the weighed average of the materials originally
composing the volume. Some thermal properties have been further adjusted to
reflect the response of tissues to thermal stress: muscle perfusion is increased
by a factor 4 due to the systemic response to heat [76], tumor perfusion is
decreased by a factor 0.7 to account for its chaotic vasculature [79], and the
thermal conductivity of the cerebrospinal fluid is increased by a factor 10 to
emulate the convective transport of heat [42].
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3.2 Simulation techniques
The next step in treatment planning optimization is to perform electromag-
netic and thermal simulations [59], [62], by inserting the patient model in
a virtual model the applicator in use, which also includes the water bolus.
The first simulation computes the E-field and power loss distributions gener-
ated by each antenna. A number of electromagnetic simulation methods have
been described in the literature, either based on the differential or the inte-
gral form of Maxwell’s equations. The electromagnetic field distribution can
be calculated using either the finite-difference time-domain (FDTD) method
or the finite-element (FEM) method. Both methods have seen wide appli-
cation in biomedical engineering. Generally speaking, the FDTD method is
more frequently used in hyperthermia treatment planning as it relies on hex-
ahedral grids which are easier to interface with patient voxel models. To
avoid reflections of the electromagnetic waves at the boundaries of the com-
putational domain, several variations of absorbing boundary conditions can
be used. Among them, the perfectly matched layer [80] is considered as the
the most effective. Once the E-field distributions are available, the resulting
power loss distribution relative to each operating frequency is calculated by
superposition after steering each channel in amplitude and phase according to
the treatment plan (Section 3.4). The electromagnetic energy of the traveling
wave is converted into heat as a consequence of the lossy nature of the tissue.
The amount of energy absorbed in each point can be described by the SAR







where σf is the tissue conductivity at frequency f , ρ is the tissue density,
and Ef the total electric field at this frequency. In a multi-frequency treatment
plan, the overall power deposition can be obtained as the sum of the single
frequency components:
SAR = SAR1 + SAR2 + . . .+ SARf (3.2)
The resulting temperature distribution inside the patient is estimated by
means of a second, thermal simulation where the SAR term is included as
a distributed heat source. The standard thermal modelling in hyperthermia
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where ρ is the tissue’s density, c the tissue’s specific heat capacity, T the
temperature, t is time, k is the tissue’s thermal conductivity, ω is the tissue’s
blood perfusion coefficient, ρB is the blood’s density, cB is the blood’s heat
capacity, TB is the blood’s temperature, and Q is the heat generated by the
tissue’s metabolic activity. In the term representing the externally applied
heat, the SAR is converted into volumetric power loss density (PLD). Pennes’
equation describes the tissue’s thermal behavior as a first-order dynamic sys-
tem. By setting the time derivative on the left-hand side to zero, the steady
state temperature distribution can be obtained, which shows the predicted
location of hot spots and tumour temperatures. On this distribution, the
temperature-based hyperthermia treatment quality indicators can be evalu-
ated (Section 3.3) and the treatment’s viability can be decided. In this work,
the well established commercial software CST Microwave Studio R© is used for
both electromagnetic and thermal simulations [82].
3.3 Treatment planning quality indicators
The goal of hyperthermia treatments is to achieve the prescribed thermal dose
in the entire clinical target volume. For this to be possible, the thermal dose
has to be defined with a quantitative measure. Since the therapeutic effect is
reached by a combination of temperatures above 40 ◦C and prolonged expo-
sure time, the dose metric has to capture these two notions simultaneously.
To this end, the Cumulative Equivalent Minutes at 43 ◦C (CEM43) metric
has been proposed [83] and adopted in clinical trials [84]. The temperature
exceeded by x % of the target volume is used as lumped temperature value
for the evaluation of the metric, yielding CEM43Tx, where x can be 90 or 50.
The applicability of this metric in the context of the actual sub-optimal tem-
peratures achieved in the clinics has been debated, but there appears to be
consensus in that the metric represents a good measure of the overall thermal
dose [30], [85].
In view of this, the treatment planning stage, where the steady-state tem-
perature distribution is estimated and optimized, should aim at maximizing
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the temperatures in all parts of the tumor, with the only constraint of the max-
imum tolerable temperature in healthy tissues. According to the CEM43Tx
definition, we can assess the steady-state distribution using precisely the tem-
perature indicators T90 and T50. These, in turn, have been shown to correlate
with the SAR-based indicators TC50 and HTQ when applied retrospectively
to clinical data sets [86], [87]. These indicators are defined as follows:




i.e. the ratio between the average SAR in the sub-volume containing
the highest 1-percentile SAR among the remaining tissues (SARR1) and
the average SAR in the target volume (SART). Values of HTQ around
or below 1 are typically considered for clinical treatment.




, VT(x) | SAR[VT(x)] ≥ x · SAR[V ] (3.5)
i.e. the fraction of the target volume VT where SAR values are above
a given fraction x of the SAR peak value in the whole patient volume
V . Both the TCx value and the fraction x are usually expressed as
percentage, and the TCx index is evaluated in this work for x = 25 %
or x = 50 % depending on the model at hand. Values of TC25 greater
than 75 % are typically considered for clinical treatment.
This correlation enables the use of SAR as a surrogate for the temperature
distribution during the treatment planning optimization process, thereby sav-
ing in model complexity and computational resources. In particular, TC25
has been shown to directly correlate with clinical outcome [89].
However, point SAR, as given in Equation 3.1, has little value in terms
of temperature prediction. In fact, Pennes’ equation (3.3) acts as a spatial
low-pass filter on the heat sources, while the SAR distribution is evaluated
at the individual grid points and can therefore exhibit sharp changes at the
tissue interfaces. Consequently, if the SAR distribution has to be used as
surrogate for the temperature, the point SAR has to be smoothed according
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to some averaging scheme. For instance, in SAR exposure standards for mobile
phones and other body-contact RF devices, the evaluation of absorption peaks
is carried out over a mass-averaged SAR distribution [90]. This approach is
also adopted in hyperthermia treatment planning, and the averaging scheme
involves the use of a convolution kernel whose size is increased until the mass
of patient tissue within reaches a specified amount. The SAR values outside
the patient are excluded from the average, thus preventing surface hot-spots
from being potentially overlooked. The amount of averaging mass is however
a matter of debate [91]–[94]. The consensus for low, non-medical exposures
seems to lie on 10 g, which is also adopted in technical standards. For higher
thermal doses, 1 g SAR mass averaging seems to be a better predictor of the
temperature distribution [95]. During our internal evaluations, we noticed
that the 1 g-based hyperthermia treatment optimization in the brain region
leads to higher tumor temperatures than a 10 g-based one. Once again, this
might be a result of the particular anatomy of the head, where the skull
(≈ 6 mm, [72]) is adjacent to a thin layer of skin (≈ 5 mm, [96]) on one
side and cerebrospinal fluid (≈ 4 mm, [97]) on the other. All these tissues
exhibit considerably different dielectric and thermal properties. In a rough
estimation, assuming the kernel to be cubic and its contents homogeneous,
the averaging cube for cortical bone (ρ ≈ 1900 Kg/m3, [60]) would be of side
≈ 1.7 cm in the 10 g case and ≈ 8.1 mm in the 1 g case . Conversely, in
the case of skin or cerebrospinal fluid (ρ ≈ 1000 Kg/m3, [60]), the cube side
becomes ≈ 2.1 cm (10 g) and ≈ 1.0 cm (1 g). Of course, where the cube is not
entirely filled with a single tissue or part of it lies outside the patient, its size
will vary in between these values or increase further. When compared with the
anatomical layer thicknesses, these estimations suggest that 10 g averaging is
too coarse to capture the location and severity of hot-spots in the superficial
areas of the brain region, which absorb most of the incoming wave. Therefore,
we opted for a 1 g SAR mass averaging scheme for all the treatment planning
optimizations and distribution analyses reported in this work. The averaging
scheme is similar to the CST Legacy one as described in [98], albeit with a
spherical kernel rather than cubic.
23
Chapter 3 Treatment Planning
3.4 Treament planning optimization
Many approaches to determine the optimal amplitudes and phases for each
antenna in the applicator have been proposed, as summarized in excellent re-
views [59], [62]. These steering settings aim at maximizing the thermal dose as
described in the previous section. In particular, the multiple objectives of the
hyperthermia treatment plan optimization problem, i.e. high target temper-
atures with extensive coverage and limited temperature increase in healthy
tissues, are mathematically described by a lumped cost function. Different
optimization algorithms, either direct or iterative, are then applied to solve
for this cost function.
Cost functions for SAR-based optimization
In a study by Canters et al. [63], a number of cost functions for SAR-based
treatment planning were summarised and analysed in terms of their correlation
with the temperatures achieved in the patient. As a result, the HTQ (Equation
3.4) was proposed and implemented in the clinical routine at the Erasmus
University Medical Center, Rotterdam, The Netherlands [86]. Another, widely
used, cost function is the target-to-remaining average SAR ratio defined in the




where SAF stands for SAR Amplification Factor, SART is the average SAR
in the target, and SARR is the average SAR in the remaining healthy tis-
sues. The main benefit of SAF is that a ratio of quadratic polynomials in the
unknowns (the steering parameters) can be solved directly using eigenvalue
(EV) decomposition. When the resulting SAR (or temperature) distribution
is showing overheated healthy regions, a weighing factor can be introduced
to iteratively reduce the power deposition at those locations [100], [101]. EV
is a direct method that provides a fast and deterministic solution and has
therefore been used extensively in clinical hyperthermia treatment planning.
However, it is unclear whether solving for the maximum SAF ratio actually
yields the highest and most homogeneous possible temperature distribution in
the tumour. In fact, the analysis of Canters et al. [63] revealed that quadratic
cost function predictions correlate poorly with the temperature rise in the tar-
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get volume during clinical treatment. Yet, still to date, SAF and EV-based
optimization methods are considered a means to evaluate the heating capabil-
ities of an applicator design prior its clinical use [102]–[104]. Furthermore, the
role of the SAF ratio as a cost function for multi-frequency UWB treatment
planning remains unclear.
We have therefore investigated the suitability of EV and SAF for single- and
multi-frequency hyperthermia treatment planning [105], Paper A. We showed
that the SAF ratio (3.6) cannot be maximized by more that one frequency at a
time. In particular, even when the EV solver is complemented by an iterative
optimization procedure that minimizes for another cost function, for instance
the HTQ as in [101], the final solution will always consist of only one operating
frequency, regardless of how many frequencies are available for concomitant
treatment. Is this a problem for deep microwave hyperthermia? Is it a strong
limitation to use only one frequency for treatment, as long as this frequency
can be selected across a wideband range? Can the use of multiple operating
frequencies improve target coverage and hot-spot suppression thanks to their
complimentary interference patterns? To answer these questions, we went a
step further and analysed two realistic test cases, a tumor in the larynx and a
tumor in the meninges. We compared the resulting temperature distributions
when a single frequency is used, to the case when two simultaneous frequencies
are jointly optimized with respect to their overall SAR distribution. The latter
optimization had to be carried out using some other cost function than (3.6)
and a solver other than EV (in this case, the Particle Swarm global stochastic
optimizer). Results for the larynx indicated that a single frequency treatment
is sufficient to reach satisfying values of T50 and T90 in this region, and that
adding a secondary frequency would not improve the thermal distribution
further. However, in the brain case, introducing a second frequency would
increase SAR target coverage, TC50, by 10 points, and temperature coverage,
T90, by 0.5 ◦C with respect to the best single-frequency solution (from 40.9 ◦C
to 41.4 ◦C). In terms of CEM43T90, such an increase would correspond to a
doubling of the thermal dose. This means that multi-frequency systems do
have the potential to improve hyperthermia treatments in regions typically
difficult to treat such as the brain.
A relevant question to be asked at this point is: if SAF is not an appropriate
cost function for treatment planning optimization, what cost function should
be used to fulfill all the requirements of hyperthermia treatments and to fully
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exploit the potential of multi-frequency systems? At a first glance, the HTQ
(3.4) seems to be a promising candidate. The definition of HTQ includes a
non-linear term through the evaluation of the highest 1-percentile SAR in the
healthy tissues. Because of this, it is not subject to the single-frequency limi-
tation that affects SAF. As mentioned before, HTQ is also used as treatment
quality indicator, and the correlation of its inverse, 1/HTQ, with the temper-
ature increase in the target has been shown. However, HTQ is not the sole
SAR-based treatment quality indicator. TC25 and TC50 (3.5) need also be
evaluated to determine the viability of a plan prior to treatment. Yet, the
relationship between these indicators is not straightforward. It is unclear, for
instance, whether they assess contrasting objectives in treatment planning or
if their optimal SAR distributions correspond. Furthermore, the limitations
of both indicators when used as cost function for treatment planning opti-
mization should be clarified. The HTQ aims at suppressing the most relevant
hot-spot in the healthy tissues while raising the average power deposition in
the target. Therefore, it does not account for inhomogeneities of the SAR
distribution inside the target volume. As a direct implication, a low HTQ
value, which would suggest a "good" plan, can be achieved with SAR distri-
butions comprising narrow localized peaks in the tumor, while leaving most
of the target volume uncovered and untreated. On the other hand, the TCx
indicator, when used as cost function, aims at extending the SAR coverage
throughout the target volume with respect to a fixed fraction of the overall
SAR peak inside the patient. This implicitly neglects the possibility to deliver
more raw power to the target, i.e. when the SAR in the target can exceed
this fixed fraction of the peak.
In view of these considerations, we investigated the relationship between
HTQ and TC50 [106], Paper B. In this study, we considered the two realis-
tic test cases of the larynx and of the meningioma and obtained the optimal
treatment plannings with respect to HTQ and TC50 by means of a global
stochastic optimizer (Particle Swarm). The results confirmed that the two
indicators assess different and not necessarily correlated aspects of the hyper-
thermia treatment plan. In particular, optimizing for the HTQ often yields
too low values of TC50, indicating poor coverage. An parallel issue occurs
when optimizing for TC50: the resulting HTQ is systematically high. Values
of HTQ above 1 indicate the presence of a prominent hot-spot that may limit
the temperatures achieved in the tumor during treatment. Consequently, we
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proposed a novel cost function for hyperthermia treatment planning whose
aim is to combine the aspects assessed by HTQ and TC50 into one metric.





where SARV indicates the average SAR in volume V, while Rq (Tp) repre-
sent the q-percentile (p-percentile) sub-volume of healthy (tumor) tissue with
highest (lowest) SAR. The relationship between the two percentiles is fixed
and defined by:
q = p |T |
|R|
(3.8)
where |V | is the size of the volume V . In this study, the cold-spot percentile
p was chosen to be 10 % of the tumor volume. As in the HTQ, the purpose
of the hot-spot term in the numerator is to suppress potentially treatment-
limiting SAR peaks in the healthy tissues. The cold-spot term in the de-
nominator, on the other hand, makes sure that all areas of the target volume
are covered by sufficient SAR deposition for homogeneous heating. The rela-
tionship (3.8) guarantees that the HCQ is always normalized to the patient
and target volume, rendering values of HCQ from different plans comparable.
When used as cost function for the treatment planning optimization of the two
realistic test cases, the HCQ revealed a good ability to yield solutions exhibit-
ing both low HTQ and high TC50. Moreover, the HCQ provided consistent
results for both single- and multi- frequency settings. More importantly, given
a discrete set of possible operating frequencies to choose from, the HCQ-based
optimizer could always determine a combination of one or more frequencies
that exhibited HCQ and TC50 close to their globally optimal values for the ex-
amined cases. It could be concluded that the single cost function formula (3.7)
provides the means for an effective multi-frequency treatment plan optimiza-
tion and enables meaningful comparisons between a large number of potential
treatment solutions. Naturally, future work should include a thermal valida-
tion of the relationship between the HCQ and the thermal indicators T50 and
T90, ideally on clinical data sets.
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Algorithms for optimization
While non-linear cost functions yield more clinically relevant treatment plan-
ning solutions than quadratic ones, the price to pay is the impossibility to
directly determine these solutions. Unlike the SAF ratio, non-linear cost func-
tions require iterative optimization schemes. In modern clinical planning tools,
the optimization is carried out by global stochastic optimizers, mainly Parti-
cle Swarm (PS) [107]. Another alternative is the use of genetic algorithms, as
they allow for multi-objective optimization [108]. While these solvers can find
the global optimum of any given problem with high probability, they suffer
from slow execution times, while demanding large computational resources.
This drawback conveys relevant limitations for online treatment planning re-
optimization, which is mandatory in clinical practice [57]. As discussed above,
planning tools based on stochastic optimizers require coarse patient model
resolutions to maintain real-time usability. However, for intracranial hyper-
thermia treatments, denser sampling grids and more detailed patient models
are necessary. This calls for faster alternatives to stochastic optimizers. So
far, only few UWB solvers have been suggested, with a vast majority of them
involving the use of quadratic-programming optimization [50], [53], [109]. As
such, these solvers cannot be applied to non-linear cost functions, and neither
are they able to return the HCQ-optimal distribution. Consequently, there
is a need for fast iterative UWB solvers that can solve for non-linear cost
functions.
One promising such method is Time Reversal (TR). TR-focusing is a fast,
intrinsically wide-band and deterministic method that has been proposed and
validated as an alternative treatment planning optimization technique for mi-
crowave hyperthermia [110], [111]. TR processing is a well characterized in-
verse filter initially developed for focusing ultrasound pulses generated by
transducer arrays inside a biological target [112], [113], and subsequently ex-
tended for use with electromagnetic antenna arrays [114]. It exploits the time
and space reciprocity of the wave equation to determine the optimal phase
and amplitude settings of an array of radiators that will cause the highest
constructive interference to occur at the desired location. In its basic im-
plementation, with a single virtual source placed at the center of the tumor,
TR yields solutions that exhibit good target coverage [49], [111], [115] al-
beit far from the global TCx optimum. Further improvements for hot-spot
management in TR have been proposed for high-intensity focused ultrasounds
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(HIFU), based on iterative methods [116]. In general, the major hindrance
for the clinical introduction of TR-based treatment planning optimization is
its limited ability to suppress hot-spots.
Figure 3.3: Simplified description of the proposed iterative time-reversal scheme.
The blue section indicates a set of cold-spot (phase) iterations, while
the red section refers to a set of hot-spot (amplitude) iterations.
To improve hot-spot suppression and target coverage in TR-based treatment
planning, we proposed a novel deterministic UWB TR-based iterative scheme
(i-TR) [117], Paper C. The scheme aims at minimizing the HCQ (3.7) and is
specifically tailored to this purpose. The procedure, Fig. 3.3, is initialized at
the classic TR solution obtained by placing a virtual source at the center of
the tumor mass. The resulting (time reversed) SAR distribution is analysed
and the most prominent cold-spot is identified as the p-percentile sub-volume
of the target containing the lowest SAR values. A virtual source is placed at
the center of the cold-spot and a TR solution for focusing at that location
is determined. Similarly, the most prominent hot-spot is identified as the q-
percentile sub-volume of healthy tissues containing the highest SAR values.
A virtual source is placed at the center of the hot-spot and a TR solution for
focusing at that location is determined. The algorithm then selects the first
operating frequency in the set and begins improving the current solution by
progressively shifting each channel’s steering phase towards the phase of the
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cold-spot solution. At each step, the HCQ is evaluated over the focused SAR
distribution and the new solution is deemed improved if the HCQ exhibits a
lower value than the previous. Subsequently, the solution is further improved
by progressively shifting each channel’s steering amplitude away from the
amplitude of the hot-spot solution (i.e., towards the inverse of the hot-spot
solution’s amplitudes). If the HCQ does not improve, the next frequency in
the set is selected and a new attempt is made to improve the solution. Once
the HCQ does no longer improve by either a cold- or a hot-spot step at any
frequency, the SAR distribution is re-evaluated and a new pair of cold- and
hot-spot are identified and their TR solutions computed. The whole procedure
is then reiterated until the new set of cold- and hot-spot solutions does not
bring any improvement in HCQ. The algorithm then halts and the latest
solution with lowest HCQ is returned as the optimized treatment plan.
In this study, we show that i-TR yields results comparable to those obtained
via global stochastic optimization, while being significantly faster. The algo-
rithm is benchmarked numerically for two different applicator array topolo-
gies: a collar for tumors in the neck and a helmet for tumors in the brain.
For the neck model, different target locations and sizes are considered, to as-
sess the algorithm’s robustness to different scenarios. The algorithm is also
applied to two realistic cases, a tumor in the larynx and one in the meninges.
For each test case, treatment planning quality and performance indicators are
computed and compared against those obtained with EV, PS and classic (non-
iterative) TR. Results suggest that the method is successful in finding viable
multi-frequency solutions for a given problem, independently of the target’s
size, location, morphology or composition. They further indicate that the
method is robust to problems involving mixed polarization axes. The quality
of the i-TR solution can depend on the selected set of operating frequencies,
however the high execution speed makes it possible to evaluate all frequency
combinations and always determine one viable solution. The treatment plans
obtained via i-TR are further validated with thermal simulations. We verify
that i-TR can achieve the same tumor temperatures (T50) as the treatment
plans based on global PS-based HTQ optimization. In the larynx case, i-TR
outperforms the HTQ-based plan by 0.4 ◦C, potentially confirming HCQ’s




The electromagnetic energy is delivered to the patient by an antenna applica-
tor. The temperature elevation in deep seated targets is often better achieved
with a phased-array, i.e. a set of coherently driven antennas placed around
the patient. The antennas are suitably fed in amplitude and phase to create
a constructive wave interference to selectively heat the target region. The
steering parameters are optimized during treatment planning as discussed in
the previous chapter. Currently, all clinically utilized microwave applicators
operate at a single frequency and consist of one or more concentric rings of
antennas whose polarization is aligned with the symmetry axis [14]. In these
applicators, the antennas are immersed in a common water bolus, Fig. 4.1,
which fills the gap between the patient and the array. Beyond skin cooling
and impedance matching, the water bolus also serves as a high permittivity
medium to reduce the antenna size. Several parameters can be varied in this
design to achieve the desired power loss distribution pattern, and they have
been investigated in many studies [45], [118]–[120].
The design parameters typically include: the operating frequency, the ra-
dius of the circular or elliptical arrangement, the number of rings, the number
of antennas per ring. The optimal combination of these parameters depends,
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Figure 4.1: Clinical dual-ring applicator design, example in the neck region. The
light blue shade represents water. The antennas are indicated with a
pin following their main polarization direction.
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in a more or less direct manner, on the operating frequency itself. The choice
of operating frequency, in turn, determines the size of the resulting focal spot
and the penetration depth [121]. For compliance, the operating frequency is
usually selected among the limited set of frequencies allocated for medical use
in the regulated spectrum. Therefore, the vast majority of systems operate at
434, 915 MHz or 2.45 GHz. Systems deployed for use in shielded rooms can
operate outside the ISM bands and utilize lower frequencies for deeper penetra-
tion. In the pelvic and abdominal regions, for instance, the typical operating
frequency is between 70 and 140 MHz. Accordingly, the consolidated recipe
for the design of a single-frequency applicator involves the following steps: 1.
determine the operating frequency based on the region to be treated, 2. choose
a narrow-band directional antenna at the target frequency, 3. determine the
best array arrangement based on the previous constraints (and other external
constraints such as space, cost, etc.). The clinical systems used nowadays for
treatments of tumors in the pelvic region, the abdomen, and the head and
neck, have mostly been designed according to this approach [120].
In the UWB setting, this approach is no longer applicable. The design of
UWB systems cannot be based on the target operating frequency, precisely
because this is no longer defined. Rather, an operating band must be chosen.
This band can span more than an octave and is only constrained by external
factors, such as the (commercial) availability of RF components and their cost.
In fact, in terms of deep microwave heating, the operating band can be located
anywhere between ≈ 1 MHz and ≈ 1 GHz. Beyond this limit, the penetration
depth of the impinging wave becomes gradually irrelevant and its effect on the
body temperature can only be seen within a few centimeters from the skin
surface [25]. The actual penetration depth obtained by a conformal array
of antennas is higher thanks to the array effect, but similar considerations
apply. In general, lower frequencies have to be included to support heating
at depth, while higher frequencies can contribute to the spatial refinement of
the thermal dose distribution. The microwave hyperthermia system for head,
neck and brain treatments that is being developed at Chalmers features 16
channels designed to operate across the 300 ∼ 800 MHz frequency band. The
diameter of the smallest achievable focal spot (λ/2) at 300 MHz is ≈ 5.3 cm
in water, while at 800 MHz this diameter is ≈ 2.0 cm.
The possibility to choose any operating frequency within the band adds
another degree of freedom in the array applicator design, namely the antenna
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size. The ideal antenna for UWB treatments should in fact exhibit the fol-
lowing characteristics:
• high return loss (> 10 dB)
• high directivity (> 10 dB)
• low cross coupling (< −10 dB) between nearby elements
• high operating power (≈ 150 W)
• small size (< λ2 )
across the entire operating band. Unfortunately, when the target frequency
band spans more that one octave, it is nearly impossible for any antenna de-
sign to fulfill all these requirements simultaneously. Thus, instead of relying
on a single antenna type, one can consider scaled versions of the same octave-
antenna to cover different (and possibly overlapping) ranges within the wider
operating band of the RF amplifier system. The brain applicator being devel-
oped at Chalmers features two sets of antennas, a bigger one working across
the 300−600 MHz range and a smaller one for the 400−800 MHz range. These
antennas are implemented using a self-grounded bow-tie (SGBT) design and
exhibit small electrical size and naturally high directivity [122]. The further
reduce back-radiation, size and cross-coupling between nearby antennas, each
antenna is immersed into a separate water bolus [123], Fig. 4.2a.
In addition to the possibility to choose among different antenna sizes intro-
duced by the UWB setting, the design of an applicator for the brain region
allows for yet another degree of freedom. Unlike for other body parts, in
fact, the array morphology is not limited to concentric rings of antennas, as
visualized in Fig. 4.3a. The array can rather be entirely conformal to form
a helmet around the head, fully exploiting the surface available on the scalp,
Fig. 4.3b. In terms of heating capability, the inclusion of more antennas at
different angles can lead to better tumor coverage [52]. Furthermore, these
antennas can be polarized in different directions to compensate for the distor-
tions and irregular wave scattering introduced by the strongly heterogeneous
anatomy of this region. In other words, considering the antenna polarization
direction as a design parameter might increase the net average power deliv-
ered to the target while reducing the entity of SAR peaks in the surrounding
healthy tissues.
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(a) Antenna Model (b) Reflection Coefficient
Figure 4.2: The 400 − 800 MHz SGBT antenna for brain applicators. The blue
shade indicates water. b) reports the reflection coefficient when the












Figure 4.3: Collar versus helmet applicator topology. The antennas are indicated
by black pins. The focal spot is indicated with a red dot, and the
E-field of each channel at this location is indicated with a red arrow.
In the helmet case, the resulting E-field polarization at the focal spot
cannot be determined right away, as the antennas contribute each with
a different angle to the power deposition at the focus.
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As discussed in the previous chapters, the brain region requires extraordi-
nary control in the delivery of heat to avoid damage to life-critical organs. To
achieve this accuracy, how many small and big antennas should the optimal
brain applicator consist of? How should they be arranged around the head?
How should they be rotated to fully exploit the polarization diversity? The
commonly used strategies in antenna applicator design, based on single pa-
rameter studies, are inadequate to tackle all the additional degrees of freedom.
We believe that the logical step forward in applicator design is to combine all
the design parameters into a global optimization process. This would consider:
• operating frequency
• number of antennas
• size of each antenna
• location of each antenna
• rotation of each antenna
The goal of the optimization is to find the antenna arrangement that yields
maximum target coverage and hot-spot suppression, i.e. high TC50 and
low HTQ, for a given patient. The optimization can be carried out with
a global stochastic optimizer configured to solve for the hot-to-cold spot quo-
tient (HCQ), described in Section 3.4. The number of antennas should always
be the highest possible to maximize the array effect and is only limited by the
available water bolus surface. At the same time, it is well known that for a
given patient and target volume, only a subset of the array is typically active
during treatment [103], [124]. This fact allows us to treat the number and
size of antennas as fixed design parameters and optimize for the rest. The
optimization can then be repeated for a few test sets to qualitatively deter-
mine the best compromise for these parameters. Thus, for a given size and
number of antennas, the optimization variables are the coordinates of each
antenna around the scalp together with its rotation angle. Since all these
variables are defined on continuous intervals, they are suitable for use with
efficient global and local optimization algorithms. These algorithms are typ-
ically iterative, and they require an evaluation of the cost function for a new
candidate solution at each step. Since each new solution corresponds to a
previously unexplored array configuration, both the E-fields and the steering
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parameters have to be determined anew. Ideally, the evaluation of the cost
function consists of two stages:
1. Simulate the UWB wave propagation for each antenna in the current
array configuration.
2. Determine the HCQ-optimal steering parameters to focus in the target
volume and use this HCQ as cost function value.
Step 1 can be particularly time consuming and resource demanding. In a
realistic case of a 16-channel UWB applicator, a full array simulation at the
appropriate resolution cast last hours with a commercial FDTD scheme, even
on a modern GPU. At the same time, a global optimization procedure with 3
variables for each antenna can take up to thousands of iterations to complete.
Consequently, for the optimization to be feasible, the evaluation of the cost
function should run within minutes. Having developed a fast UWB treatment
planning algorithm in Paper C to carry out Step 2 in reasonable time, we
need to accelerate the procedure in Step 1. In the next section, we introduce
an E-field approximation method that allows for the rapid estimation of the
field distribution generated by each antenna at any location and polarization
angle around the head.
4.1 Fast E-Field Interpolation and Array
Evaluation
In [125], Paper D, we presented a novel field interpolation technique that al-
lows for a quick estimation of the E-field distributions generated by a particu-
lar array arrangement at any operating frequency. The interpolation is based
on a pre-calculated set of E-field distributions generated by a single antenna
at fixed locations around the head, forming an interpolation grid, Fig. 4.4.
For each location, two orthogonal polarization directions are simulated. The
E-field generated by an antenna at a specific location and rotation is then ob-
tained by a weighed average of the three nearest sampled locations (triangular
patch). Note that this approach does not account for cross-coupling effects
between nearby antennas, which might affect the power deposition pattern
inside the patient. However, thanks to their separate water-boli, the SGBT
antennas used in our system exhibit low coupling (< −15 dB). It is therefore
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possible to neglect the secondary fields passively generated by nearby resonat-
ing antennas and superpose the single antenna distributions to obtain a good
estimation of the overall array pattern.
(a) Single Antenna Setup (b) Interpolation Grid
Figure 4.4: E-field interpolation method. A single antenna (a) is simulated at a
number of fixed locations around the head (b). The E-field due to an
antenna at query location Q is determine by linear weighed interpola-
tion of the simulated E-fields at grid locations G1, G2 and G3.
In this study, the method was applied to the optimization of an illustrative
case of applicator consisting of 8 antennas of the same size and a single-
frequency treatment plan. The method was validated indirectly by comparing
the improvement in APA (average power absorption, [102]) obtained by the
optimized array versus a standard ring array to the improvement in APA
indicated by a full FDTD simulation of the same two array configurations.
The method was able to reflect the improvement in APA, which indicates
that the optimization procedure based on the field approximation is effectively
leading to a lower cost function value and better antenna arrangement for the
specific patient.
In further, yet unpublished material, we have determined the actual ap-
proximation error by comparing the interpolated distribution with the fully
simulated E-field of a single antenna at the same location and rotation. The
errors due to varying location and rotation were assessed separately in two
sweeps, Fig. 4.5. We provide a summary of the results in words:
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(a) Location Sweep (b) Rotation Sweep
Figure 4.5: The location and rotation sweeps used to assess the error of the inter-
polated E-field approximation. The antenna location is indicated by
a black dot. The main polarization axis is indicated in red, and the
radiation direction in blue. The yellow circles indicate the locations of
the closest grid points forming the local triangular patch for interpo-
lation. In (a), the antenna is moved in 5 steps from a simulated grid
location towards the opposite edge via the center of the patch. In (b),
the antenna is located at a grid point and its polarization is rotated in
5 steps between the two orthogonal simulated directions.
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1. The approximation seems to be robust regardless of the operating fre-
quency.
2. Location changes introduce an average error less than 3 % in phase and
10 % in radiation direction, while the amplitude error can reach as much
as 37 % when the query location is far from the sampled grid locations.
3. The worst overall distribution error is around 26 %, which is acceptable
for array optimization purposes.
4. The approximation of changes in the antenna’s polarization angle is
almost exact, with all errors lying below 5 % of the actual simulated
distribution.
In conclusion, the results motivate the use of the proposed field interpolation
technique for quick array evaluation and optimization.
4.2 Helmet array optimization: preliminary results
In this section, a preliminary investigation of the optimal helmet applicator
configuration to treat a pediatric medulloblastoma patient is outlined, Fig.
4.6. Using the particle swarm global optimizer together with the fast UWB
E-field approximation method and the fast i-TR UWB treatment planning
algorithm described in the previous sections, we have obtained a first esti-
mate of the HCQ-optimal array configuration consisting of 4 low-frequency
(a) Transverse (b) Sagittal (c) Coronal
Figure 4.6: Model of a pediatric patient showing a large medulloblastoma, high-
lighted in red. Sections taken at tumor center.
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antennas (300 − 600 MHz) and 4 high-frequency antennas (400 − 800 MHz).
The optimization was carried out for the [300, 400, 500, 600, 700, 800] MHz set
of operating frequencies.
(a) Front (b) Left (c) Right (d) Top
Figure 4.7: Resulting helmet applicator antenna arrangement for the treatment of
a large medulloblastoma in a pediatric patient. The array consists of
4 larger and 4 smaller antennas, operating at different and partially
overlapping frequency bands.
Despite the large target volume, the final array arrangement, shown in Fig.
4.7, yields an HTQ value of 1.8 with quite an impressive TC25 at 83 %. In
the subsequent thermal validation, Fig. 4.8, the achieved tumor temperatures
are T90 = 38.6 ◦C and T50 = 39.7 ◦C while all healthy tissues are kept
below a conservative temperature threshold of 42 ◦C. The limiting hot-spot
emerges, as expected, in the cerebrospinal fluid adjacent to the brainstem.
These encouraging results indicate that microwave heat delivery into large
intracranial tumors is feasible and motivate the further development of specific
applicators for this site.
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(a) Transverse (b) Sagittal
Figure 4.8: Temperature distribution obtained in the medulloblastoma patient us-
ing the optimized helmet applicator. The maximum temperature in all
healthy tissues is 42 ◦C.
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Ongoing Work and Outlook
This thesis deals with different aspects of the development of UWB hyper-
thermia applicators to treat intracranial tumors. The results indicate that
non-invasive UWB microwave hyperthermia is a viable treatment option in
this location and that more research efforts should be spent in this direc-
tion. Patient-specific array design and treatment planning optimization can
increase the tumor temperatures and the thermal dose to the levels required
to achieve a therapeutic gain when combined with other treatment modalities.
Nevertheless, from an engineering perspective, the task remains a challenge
and has to be tackled from many angles. The development of a robust, reli-
able and safe microwave hyperthermia system is not limited to the design of
a good applicator. A large number of practical issues has to been taken into
account and solved before such a system can be adopted for clinical use.
First of all, the applicator has to be backed by a reliable RF amplifying
system. Each channel in the RF cascade must be able to be steered in ampli-
tude and phase at any frequency of the operating band within the necessary
precision. The hyperthermia system and the clinical setup have to match the
accuracy required for the treatment plan to be meaningfully applied [126].
The treatment plan optimization, in fact, assumes that the virtual model
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corresponds exactly to the actual setup during a treatment sessions. Unfor-
tunately, this is often not the case [127], as the patient and the applicator
can be slightly misplaced with respect to each other. Furthermore, the cur-
rently used water-boli are prone to unpredictable shape deformations due to
their thin plastic casings, and can also be subject to air leakages when the
internal water pressure is insufficient. The presence of air bubbles and plastic
layers between an antenna and the patient is detrimental for the treatment, as
they cause unpredictable wave scattering and thus differences in the resulting
power deposition pattern. A summary of possible mismatches is reported in
Fig. 5.1.
Figure 5.1: Potential mismatches between the assumptions made by the treatment
planning optimizer and the actual treatment setup.
In parallel with a proper applicator design that can limit these uncertainties,
we have initiated a study on the possibility to use a Vector Network Analyzer
(VNA) in conjunction with the high power RF cascade to measure the scatter-
ing matrix of the applicator array, as illustrated in Fig. 5.2. The S-parameters
are measured prior to treatment in the presence of the patient. The informa-
tion contained in the S-matrix can then be processed to extract the unintended
amount of phase delay and amplitude attenuation that each antenna is sub-
ject to during the particular treatment session [128]. These values are then
subtracted from the treatment plan to compensate for mismatches between
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the treatment planning and the clinical setup, thus implementing a form of
self-calibration. The work is ongoing and experimental tests are needed to
validate the applicability of this technique in real scenarios.
Figure 5.2: Integrating a VNA into a multi-channel UWB hyperthermia system
has the potential to provide real-time feedback control of the power
deposition inside the patient.
An additional benefit of integrating a VNA into a 16-channels UWB hyper-
thermia system is the possibility to perform real-time microwave tomography
[129]. A combined imaging and treatment system could in fact allow for
the measurement of the in-vivo dielectric properties of tissues prior to treat-
ment and hopefully reduce the uncertainty in patient modelling that currently
affects hyperthermia treatment plannings. The biomedical electromagnetics
research group at Chalmers has a long-established experience in the field of
theoretical and applied microwave image reconstruction [130]. Tomography
measurements can also be performed repeatedly during treatment to track
the variations in dielectric properties due to temperature changes. The tech-
nique can be used to non-invasively obtain a map of the actual temperature
distribution inside the patient during treatment [131]–[133]. In other words,
the integration of a VNA has the potential to "close the loop" in microwave
hyperthermia treatments, providing the feedback control necessary for more
accurate power delivery. Note that, in single-frequency systems, the informa-
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tion acquired by this kind of measurement would be only limited and very
likely not sufficient for this purpose. In an UWB system, information about
the phase delay and amplitude attenuation can be obtained for the whole oper-
ating band, providing a much larger base for tomography computations. Work
is ongoing to embed a low-cost and high dynamic range VNA for tomography
measurements into Chalmers’ hyperthermia system.
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CHAPTER 6
Summary of included papers
This chapter provides a summary of the included papers.
6.1 Paper A
Massimiliano Zanoli, Hana Dobšíček Trefná
Suitability of eigenvalue beamforming for discrete multi-frequency hy-
perthermia treatment planning
Submitted to Medical Physics
24 December 2020
In this paper, we investigate whether using the eigenvalue (EV) decomposi-
tion to solve for the power deposition ratio Γ is a suitable method for single-
and multi-frequency hyperthermia treatment planning optimization. We show
that Γ cannot be maximized by more that one frequency at a time. In partic-
ular, even when the EV solver is complemented by an iterative optimization
procedure that minimizes for another cost function, the final solution always
consists of only one operating frequency, irrespective of how many frequencies
are available for concomitant treatment. We further investigate whether the
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single-frequency limitation represents a problem for deep microwave hyper-
thermia, and whether the use of multiple operating frequencies can improve
target coverage and hot-spot suppression. Two realistic test cases are consid-
ered: a tumor in the larynx and a tumor in the meninges. We compare the
resulting temperature distributions for a single frequency to the case when
two simultaneous frequencies are jointly optimized with respect to their over-
all SAR distribution. The latter optimization is carried out using non-linear
cost functions (HTQ and TC50) and a global stochastic optimizer, Particle
Swarm (PS). Results for the larynx indicate that a single frequency treatment
may be sufficient to reach satisfying values of T50 and T90 in this region, as
adding a secondary frequency does not improve the thermal distribution fur-
ther. However, in the brain case, introducing a second frequency increases
the SAR target coverage, TC50, by 10 points, and temperature coverage, T90,
by 0.5 ◦C with respect to the best single-frequency solution (from 40.9 ◦C
to 41.4 ◦C). In terms of CEM43T90, such an increase corresponds to a dou-
bling of the thermal dose. We can conclude that multi-frequency systems
do have the potential to substantially improve hyperthermia treatments in
regions typically difficult to treat such as the brain.
6.2 Paper B
Massimiliano Zanoli, Hana Dobšíček Trefná
Combining target coverage and hot-spot suppression into one cost func-
tion: the hot-to-cold spot quotient
15th European Conference on Antennas and Propagation
22-26 March 2021, Düsseldorf, Germany
In this paper, we investigate the relationship between HTQ and TC50 and
propose a novel cost-function for hyperthermia treatment planning optimiza-
tion, the hot-to-cold spot quotient (HCQ). The HCQ is intended to combine
the well known SAR metrics into one, thus enabling the concomitant opti-
mization of both. We consider two realistic test cases, a target located in the
larynx and one in the meningioma. A global stochastic optimizer is used to
obtain the optimal treatment plans with respect to all three indicators. The
results suggest that HTQ and TC50 assess different and not necessarily corre-
lated aspects of a hyperthermia treatment plan. In particular, optimizing for
the HTQ often yields too low values of TC50 for the treatment to be viable.
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An analogous issue occurs when optimizing for TC50: the resulting HTQ is
systematically high, indicating that the most prominent hot-spot might be
limiting for the treatment. When HCQ is used as cost function, the treat-
ment planning optimization yields solutions exhibiting both low HTQ and
high TC50. Moreover, the HCQ works consistently in both single- and multi-
frequency settings. Given a discrete set of possible operating frequencies, the
HCQ-based optimizer can always determine a combination of one or more fre-
quencies that exhibit HCQ and TC50 close to their globally optimal values in
the examined cases. Furthermore, the proposed definition of HCQ guarantees
that this value is always normalized to the patient and target volume, render-
ing values of HCQ from different plans comparable. It can be concluded that
HCQ provides the means for an effective multi-frequency HTP optimization
and enables meaningful comparisons between large numbers of potential solu-
tions. Future work will include a thermal validation of the HCQ-temperature
relationship on clinical data sets.
6.3 Paper C
Massimiliano Zanoli, Hana Dobšíček Trefná
Iterative time-reversal for multi-frequency hyperthermia
Physics in Medicine & Biology
16 December 2020
c©2020 Institute of Physics and Engineering in Medicine
DOI: 10.1088/1361-6560/abd41a
In this paper, we propose a novel, deterministic UWB iterative scheme
based on time-reversal (i-TR). The method, which aims at minimizing the
hot-to-cold spot quotient (HCQ), improves hot-spot suppression and target
coverage of classic time-reversal (TR) based microwave hyperthermia treat-
ment planning. The procedure is initialized at the TR solution obtained by
placing a virtual source at the center of the tumor mass. The resulting, time
reversed, SAR distribution is analysed and the most prominent cold-spot and
hot-spot are identified in the tumor and in the healthy tissues, respectively.
Two TR solutions are then determined at the cold- and hot-spot centers. The
algorithm improves the current solution by progressively shifting the steering
phases towards the cold-spot solution and the steering amplitudes away from
the cold-spot solution. The procedure is reiterated and the algorithm halts
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when the HCQ no longer improves. In this study, we show that i-TR yields
results comparable to those obtained via global stochastic optimization, while
being significantly faster. The algorithm is benchmarked numerically for two
different applicator array topologies: a collar for tumors in the neck and a hel-
met for intracranial tumors. For the neck model, different target locations and
sizes are considered, to assess the algorithm’s robustness to different scenar-
ios. The algorithm is also applied to two realistic cases: a tumor in the larynx
and one in the meninges. For each test case, HTP quality and performance
indicators are computed and compared against those obtained with eigen-
value, particle swarm and classic TR. The results suggest that the method
is successful in finding viable multi-frequency solutions for a given problem,
independently of the target’s size, location, morphology or composition. They
further indicate that the method is robust to problems involving mixed po-
larization axes. The treatment plans obtained via i-TR are further validated
with thermal simulations. It is shown that i-TR can achieve similar tumor
temperatures (T50) as the treatment plans based on global HTQ optimiza-
tion. In the larynx case, i-TR outperforms the HTQ-based plan by 0.4 ◦C,
advocating the suitability of the HCQ as cost function for optimization.
6.4 Paper D
Massimiliano Zanoli, Hana Dobšíček Trefná
Optimization of microwave hyperthermia array applicators using field
interpolation
2019 IEEE International Symposium on Antennas and Propagation and
USNC-URSI Radio Science Meeting
537–538, 7-12 July 2019, Atlanta, USA
In this paper, we present a novel field interpolation technique that allows
for the quick estimation of the E-field distributions generated by a particular
array arrangement at any operating frequency. The interpolation is based on a
pre-calculated set of E-field distributions generated by a single antenna placed
at fixed locations around the head (interpolation grid). For each location, two
orthogonal polarization directions are simulated. The E-field generated by
an antenna at a specific location and rotation is then obtained by a weighed
average of the three nearest sampled locations. The method is applied to the
optimization of an illustrative case of an applicator consisting of 8 antennas of
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the same size and a single-frequency treatment plan. The method is validated
indirectly by comparing the improvement in average power absorption ratio
(APA) obtained by the optimized array versus a standard ring array to the
improvement in APA indicated by a full simulation of the same two array
configurations. The method is shown to reflect the improvement in APA, in-
dicating that the optimization procedure based on the field approximation is
effectively leading to a better cost function value and better antenna arrange-
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